Roswell Park Cancer Institute
In 1898, Roswell Park Cancer Institute (RPCI) opened as the nation’s first cancer research, treatment, and education center. RPCI is a public benefit corporation that is internationally renowned, and is a major affiliate of the University at Buffalo School of Medicine and Biomedical Sciences. RPCI is dedicated to providing the highest quality total care to the cancer patient; to conducting research into the causes, treatment, and prevention of cancer; and to educating the public and the next generation of those who study and treat cancer.
RPCI is the only upstate New York facility to hold the National Cancer Institute designation of “comprehensive cancer center” and one of only 39 such centers in the United States. Since 1971, Roswell Park has been recognized by the NCI as a comprehensive cancer center. This designation means that the cancer center’s combined research, treatment, and educational programs have weathered extensive peer review, met rigorous national standards, and made fundamental contributions to reducing the cancer burden.
RPCI is also a member of the National Comprehensive Cancer Network (NCCN), an alliance of the nation’s leading cancer centers. A not-for-profit organization, the NCCN brings together the best minds in science to engineer continuous quality improvements in cancer care; improves the effectiveness of cancer care delivery through the ongoing collection and analysis of outcome data on a national basis; enhances communications and collaboration among member institutions; offers access to the latest, most promising clinical trials; and provides best practice guidelines and measurement tools.
Cancer research is a core element of its mission. Groundbreaking research by RPCI scientists has led to greater understanding of the nature of cancer and to major advances in cancer diagnosis and treatment that are now in use worldwide. RPCI instituted the nation’s first chemotherapy program, pioneered studies on the relationship between smoking and lung cancer and developed photodynamic therapy (PDT) and the prostate-specific antigen (PSA) blood test. A comprehensive cancer genetics program, now under development at RPCI, will rival the world’s leading programs in that field. The Institute also made significant contributions to the landmark human genome project. RPCI’s Center for Pharmacology and Therapeutics is one of the few centers in the nation capable of all phases of drug development, from the conceptual stage through manufacturing and testing. This year RPCI’s strong basic and clinical research programs attracted major research grants and contracts totaling more than $92.7 million. The Institute has sponsored or collaborated on more than 516 research funded projects of promising new cancer treatments.
RPCI is a Public Benefit Corporation founded by Dr. Roswell Park. It is under the leadership of:
- Donald L. Trump, MD, President & CEO
- Michael Joseph, Chairman of the Board
RPCI is one of Western New York’s top 20 employers with over 3,320 individuals including 275 physicians and scientists, 309 faculty members and over 626 nurses.
Web site: www.roswellpark.org